New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 29, 2015
16:41 EDTMCKMcKesson raises quarterly dividend 17% to 28c from 24c per share
Subscribe for More Information
16:40 EDTMCKMcKesson sees FY16 adjusted EPS $12.36-$12.86, consensus $12.59
16:39 EDTMCKMcKesson reports Q1 adjusted EPS $3.14, consensus $2.91
Reports Q1 revenue $47.5B, consensus $45.93B.
16:00 EDTNFLXOptions Update; July 29, 2015
Subscribe for More Information
15:08 EDTALKSNotable companies reporting before tomorrow's open
Subscribe for More Information
13:54 EDTALKSEarnings Watch: Alkermes up around 17% since last earnings report
Alkermes (ALKS) is scheduled to report second quarter earnings before the market open on Thursday, July 30 with a conference call scheduled for 8:30 am ET. Alkermes, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. EXPECTATIONS: Analysts are looking for a loss of (10c) per share on revenue of $142.8M, according to First Call. The consensus range for EPS is for a loss of (17c)-(4c) on revenue of $134.5M-$153.28M. LAST QUARTER: Alkermes reported first quarter EPS of 6c, compared to a consensus estimate of a loss of (3c), on revenue of $161.2M against estimates of $146.6M. The company reiterated all of its financial expectations for 2015 that it had previously given on March 9, when it cut its 2015 EPS view to (37c)-(50c) from (27c)-(40c). Q1 revenue from the company's anti-psychotic franchise, including Risperdal were $46.9M, compared to $49.6M for the same period in the prior year. Revenues from Amprya/Famprya were $36.5M, compared to $20.6M for the same period in the prior year. "Our results this quarter reflect strong revenues from our portfolio of key commercial products and focused investment in our promising late-stage pipeline of CNS product candidates that will drive our future growth," commented Alkermes CFO James Frates. Alkermes CEO Richard Pops noted that the company is on the "threshold" of its next growth phase and that Aripiprazole lauroxil, the company's long-acting atypical anti-psychotic for schizophrenia, is moving toward FDA approval and launch later this year. STREET RESEARCH: On June 26, Cowen said the clinical profile for Alkermes' ALKS 3831 continues to look interesting, as the firm's consultants believe data for the drug suggests a profile that would provide a significant benefit over Zyprexa for the treatment of schizophrenia. Cowen reiterated its Outperform rating and $80 price target on Alkermes shares. PRICE ACTION: Alkermes shares are up around 17% since the company's last earnings report on April 30, and are down almost 3% to $67.40 in midday trading ahead of Thursday's earnings release.
09:20 EDTMRKMerck recent weakness creates buying opportunity, says Argus
Subscribe for More Information
July 28, 2015
16:53 EDTMRKOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
16:00 EDTNFLXOptions Update; July 28, 2015
Subscribe for More Information
15:21 EDTMCKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus 85c... Altria (MO), consensus 71... General Dynamics (GD), consensus $2.06... Anthem (ANTM), consensus $2.75... Praxair (PX), consensus $1.46... Northrop Grumman (NOC), consensus $2.36... McKesson (MCK), consensus $2.91... Eaton (ETN), consensus $1.13... Humana (HUM), consensus $1.63... Hilton (HLT), consensus 23c... International Paper (IP), consensus 92c... Rockwell Automation (ROK), consensus $1.54... Jarden (JAH), consensus 59c... Quintiles (Q), consensus 70c... Tableau Software (DATA), consensus 4c... Garmin (GRMN), consensus 82c... Vantiv (VNTV), consensus 54c... ADT (ADT), consensus 49c.
12:31 EDTMRKOn The Fly: Top stock stories at midday
Stocks on Wall Street began the session in positive territory but turned mixed a short time after the open. The averages gathered themselves again and began an upward drift about an hour into trading, leaving markets near session highs around noon as stocks try to break their string of five consecutive lower closes. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rose 1.1% in May to 179.03, missing a forecast for it to rise 1.7% to 180.2. Markit's services PMI for July rose to 55.2, above the expected 55.0 reading. The Richmond Fed factory index rose to 13.0 in July from an upwardly revised 7 in June. Consumer confidence fell to 90.9 in July, down from a revised 99.8 figure for last month and below the expected reading of 100. In China, the Shanghai composite index closed down 1.7%, but only after a volatile session that saw it down as much as 5.1% and up about 1% at different points in the trading day. In Europe, U.K. GDP growth in the second quarter came in at 0.7%, matching the consensus expectation. COMPANY NEWS: Earnings season continued in earnest with UPS (UPS), Ford (F), Pfizer (PFE) and Merck (MRK) each reporting better than expected quarterly profits. UPS, which said its quarterly results gave it confidence in achieving the upper end of its earnings guidance range for the fiscal year, rose more than 5%. Pfizer and Merck each raised their fiscal year earnings guidance ranges, but Pfizer advanced 1.7% following its report while Merck slid nearly 0.5%. Ford, meanwhile, gained 1.8% after backing its fiscal year pre-tax profit view and repeating that it still expects the second half of the year to be stronger than the first half. MAJOR MOVERS: Among the notable gainers was Supervalu (SVU), which jumped 19% after the company reported better than expected first quarter results and also announced that it is exploring a separation of its Save-A-Lot business into a stand-alone, publicly traded company. Also higher was GrubHub (GRUB), which gained over 5% after reporting better than expect top and bottom line results in its second quarter and issuing 2015 guidance that analysts at Stifel said "appears conservative." Among the noteworthy losers was Immunomedics (IMMU), which tumbled 34% after the company's partner, UCB, announced that two Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus did not meet their primary clinical efficacy endpoints in either dose in both studies. Also lower following its earnings reports was Baidu (BIDU), which fell 16.5% and was downgraded by at least four research firms. INDEXES: Near midday, the Dow was up 136.13, or 0.78%, to 17,576.72, the Nasdaq was up 36.37, or 0.72%, to 5,076.14, and the S&P 500 was up 19.42, or 0.94%, to 2,087.06.
10:47 EDTNFLXUBS says YouTube paid service could be $1B business
Google's (GOOG, GOOGL) revenue could increase by about $1B or more if it decides to offer a paid, ad free version of its YouTube website in the U.S., UBS wrote in a note to investors today. The firm made the estimate based on a survey it conducted of U.S. consumers. WHAT'S NEW: YouTube remains well-positioned to benefit from the growth of online video, UBS analyst Eric Sheridan stated. After UBS conducted a survey of U.S. adult consumers, Sheridan reported that the survey found that 27% of U.S. consumers would probably subscribe to a paid, ad free version of YouTube. According to Bloomberg, YouTube has decided to launch such a service in coming months. If only 5% of U.S. YouTube users buy subscriptions to the service, Google's revenue would rise by about $943M, Sheridan estimated. Following the survey, the analyst is more confident that Google will meet his revenue estimates, which exceed consensus levels. Specifically, he predicted that Google's revenue for the second half of 2015 would come in at $32.4B, versus the consensus outlook of $31.8B, while its 2016 revenue would be $72.2B, compared with the consensus estimate of $69.7B. Sheridan kept a $750 price target and Buy rating on the stock. WHAT'S NOTABLE: Other companies that are significantly exposed to online video include Netflix (NFLX), Facebook (FB) and AOL, which has been acquired by Verizon (VZ). PRICE ACTION: In morning trading, Google Class A shares were little changed at $657.55.
09:42 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL BIDU FB NFLX F T FCX TWTR
07:20 EDTMRKBrookings Institute to hold a public meeting
Subscribe for More Information
07:11 EDTMRKMerck reports Q2 Pharmaceutical sales $8.56B
Subscribe for More Information
07:04 EDTMRKMerck narrows FY15 EPS view to $3.45-$3.55, consensus $3.45
Subscribe for More Information
07:03 EDTMRKMerck reports Q2 EPS 86c, consensus 81c
Reports Q2 revenue $9.8B, consensus $9.8B.
06:49 EDTMRKMerck to acquire cCam Biotherapeutics for $95M
Merck and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95M in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510M associated with the attainment of certain clinical development, regulatory and commercial milestones. The transaction is subject to certain closing conditions.
06:32 EDTMRKMerck's grazoprevir/elbasvir application accepted by FDA
Subscribe for More Information
July 27, 2015
16:00 EDTNFLXOptions Update; July 27, 2015
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use